Effect of Grapex on patients with Rheumatoid Arthritis

Effect of Grape seed (Grapex medicine) on improvement and relief of disease activity and severity in patients with Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180212038705N3

Enrollment

Registered

2018-07-24

Start date

2017-12-11

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: Intervention group: Grapex 100 mg daily. Intervention 2: Control group: placebo 100 mg daily.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Consent to participate in the study Patients with rheumatoid arthritis based on ACR 2010 criteria Moderate to severe disease activity based on Modified DAS28 score

Exclusion criteria

Exclusion criteria: Duration of diseases more than 5 years Concomitant use of warfarin Allergy to grapes and its components, Presence of any types of malignancy and cancer Pregnancy

Design outcomes

Primary

Measure	Time frame
Disease severity. Timepoint: At baseline and after treatment (8 week). Method of measurement: Modified DAS28 score.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and after treatment. Method of measurement: Western Green analysis.;Swollen joint count (SJC). Timepoint: At baseline and after treatment. Method of measurement: Examination and clinical judgment of the physician.;Tender joint count (TJC). Timepoint: At baseline and after treatment. Method of measurement: Examination and clinical judgment of the physician.;CRP. Timepoint: At baseline and after treatment. Method of measurement: Aagglutination test.	—

Measure

Time frame

Disease severity. Timepoint: At baseline and after treatment (8 week). Method of measurement: Modified DAS28 score.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and after treatment. Method of measurement: Western Green analysis.;Swollen joint count (SJC). Timepoint: At baseline and after treatment. Method of measurement: Examination and clinical judgment of the physician.;Tender joint count (TJC). Timepoint: At baseline and after treatment. Method of measurement: Examination and clinical judgment of the physician.;CRP. Timepoint: At baseline and after treatment. Method of measurement: Aagglutination test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Elham Rajaee

Ahvaz University of Medical Sciences

elhamrj@gmail.com+98 61 3374 3001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026